Safety and effectiveness of IMR-687 in Sickle Cell Disease
Research type
Research Study
Full title
A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease
IRAS ID
1003235
Contact name
Jo Howard
Contact email
Eudract number
2019-004471-39
Research summary
Summary of Results
The study was early terminated due to the results of the interim analysis which demonstrated that while the study drug (IMR-687) was generally well tolerated, it failed to show any meaningful benefit in transfusion burden or improvement in most disease-related biomarkers. Investigators were notified on 06 April 2022 to contact patients and instruct them to stop taking the study drug and return to the site for their last study visit. Based on these results, the sponsor decided to discontinue this study as well as future development of IMR-687 in in sickle cell disease, therefore an abbreviated CSR has been issued.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
20/LO/0785
Date of REC Opinion
24 Jun 2020
REC opinion
Favourable Opinion